$21 Billion JNJ Pact
April 29, 2011
Earlier this week, JNJ said it will buy the Swiss medical device firm Synthes for $21.3 billion. A debased U.S. dollar isn't worth much these days. Still, 21.3 billion of anything remains an impressively tall pile.
Uniquely in big pharma, JNJ has a record of megadeals that have been years ahead of peer companies. With numerous semi-autonomous…more...
Cancellations Subside
December 02, 2010
Have contract research organizations (CRO) turned the corner? Is the current downturn about to pass? Those were the questions we put to Michael Martorelli, director, Fairmount Partners.
Martorelli is a savvy Philadelphia-based observer of the CRO industry. By constitution, he is a plain-speaking and numbers-oriented guy who helps to find buyers and sellers for CROs; his firm…more...
Ugly Numbers
October 28, 2010
How bad are the job losses in pharma? How long will they last? As a starting point, every month brings new, grim numbers from Challenger, Gray & Christmas, a Chicago firm that specializes in executive recruiting.
Recent Challenger data suggest that, at the moment, the job losses in pharma are intensifying relative to other industries. In 2010,…more...
October Special Report
September 17, 2010
Is the most time-honored business model in clinical trial outsourcing out of step with our era?
Most contract research organizations (CRO) charge on the basis of time and materials. Such companies resemble construction firms that erect skyscrapers. If the design of the skyscraper changes, the builder adjusts its fee. If more steel is needed, that goes on…more...
Compliance? Huh?
What’s wrong with non-industry clinical trials, and how to fix them.
Temple, O'Neill At DIA
At the 2010 annual DIA meeting, the FDA offered two perspectives on multiregional trials
2010 Keynote Address
FDA commissioner Margaret Hamburg addresses the DIA meeting in Washington, D.C.
Thin The Herd
Norman Goldfarb discusses recent industry trends and his upcoming conference in Boston in May.
U.S. Slips On Mega Projects
As the new year begins, some reflections on the biggest clinical trials of the new year.
Fearless With Sponsors
A productive and independent Florida site works lean and doesn’t apologize for being in business.
Private Equity Buyer
The owners of Chiltern are buying MDS Pharma’s six central labs.
